HCM
BNTX icon

Hollencrest Capital Management’s BioNTech BNTX Stock Holding History

Hollencrest Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-907
Closed -$248K – 387
2021
Q3 		$248K Sell
907
-300
-25% -$95.3K 0.02% 302
2021
Q2 		$270K Buy
+1,207
New +$228K 0.02% 290

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PG
Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Hollencrest Capital Management's BNTX Position: Q4 2021 in Review

Hollencrest Capital Management sold out of BioNTech (BNTX) in Q4 2021, closing a stake of 907 shares — an estimated $248K sold.

Hollencrest Capital Management first reported a position in BNTX in Q2 2021 and held it in 2 quarters. The position peaked at $270K in Q2 2021. 354 funds tracked by Wall St. Rank hold BNTX as of Q4 2021.

  • Hollencrest Capital Management reported no remaining BioNTech position as of Q4 2021 after selling out during the quarter.
  • Hollencrest Capital Management sold 907 BioNTech shares in Q4 2021, an estimated $248K.
  • Hollencrest Capital Management first reported a position in BioNTech in Q2 2021 and held it in 2 quarters.
  • Hollencrest Capital Management's BioNTech position peaked at $270K in Q2 2021.
  • 354 funds tracked by Wall St. Rank held BioNTech as of Q4 2021.

Based on Hollencrest Capital Management's 13F filing for Q4 2021, filed 7 Jan 2022.